Conjugation of Magnetite Nanoparticles with Melanogenesis Substrate, NPrCAP Provides Melanoma Targeted, &amp;lt;i&amp;gt;in Situ&amp;lt;/i&amp;gt; Peptide Vaccine Immunotherapy through HSP Production by Chemo-Thermotherapy

Jimbow, Kowichi; Tamura, Yasuaki; Yoneta, Akihiro; Kamiya, Takafumi; Ono, Isao; Yamashita, Toshiharu; Ito, Akira; Honda, Hiroyuki; Wakamatsu, Kazumasa; Itô, Shôsuke; Nohara, Satoshi; Nakayama, Eiichi; Kobayashi, Takeshi

doi:10.4236/jbnb.2012.32020

Cited by 13 publications

(11 citation statements)

References 56 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These surface-expressed HSPs act as signals for the immune system and sensitize tumor cells for immune attack, resulting in "antitumor activity". 40 Jimbow et al 41 reported that melanoma-bearing mice treated with magnetite nanoparticlesmediated hyperthermia were able to reject rechallenge with melanoma. The authors attributed this observation to the development of antitumor activity by induction of HSP70 and HSP90.…”

Section: Discussionmentioning

confidence: 99%

Hyperthermia mediated by dextran-coated La0.7Sr0.3MnO3 nanoparticles: in vivo studies

Haghniaz

Umrani

Paknikar

2016

IJN

View full text Add to dashboard Cite

Purpose The aim of this study was to evaluate radiofrequency-induced dextran-coated lanthanum strontium manganese oxide nanoparticles-mediated hyperthermia to be used for tumor regression in mice. Materials and methods Nanoparticles were injected intra-tumorally in melanoma-bearing C57BL/6J mice and were subjected to radiofrequency treatment. Results Hyperthermia treatment significantly inhibited tumor growth (~84%), increased survival (~50%), and reduced tumor proliferation in mice. Histopathological examination demonstrated immense cell death in treated tumors. DNA fragmentation, increased terminal deoxynucleotidyl transferase-dUTP nick end labeling signal, and elevated levels of caspase-3 and caspase-6 suggested apoptotic cell death. Enhanced catalase activity suggested reactive oxygen species-mediated cell death. Enhanced expression of heat shock proteins 70 and 90 in treated tumors suggested the possible development of “antitumor immunity”. Conclusion The dextran-coated lanthanum strontium manganese oxide-mediated hyperthermia can be used for the treatment of cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Hyperthermia mediated by dextran-coated La0.7Sr0.3MnO3 nanoparticles: in vivo studies

Haghniaz

Umrani

Paknikar

2016

IJN

View full text Add to dashboard Cite

show abstract

“…Melanoma is not the most common cause of PC in humans. It is most commonly associated with ovarian cancer, malignant mesothelioma, benign papillary mesothelioma and desmoplastic small round cell tumors [ 54 , 55 ].…”

Section: Discussionmentioning

confidence: 99%

Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: a multidisciplinary study of peritoneal carcinomatosis

Nowacki

Wiśniewski

Werengowska-Ciećwierz

et al. 2015

Oncotarget

View full text Add to dashboard Cite

In general, detection of peritoneal carcinomatosis (PC) occurs at the late stage when there is no treatment option. In the present study, we designed novel drug delivery systems that are functionalized with anti-CD133 antibodies. The C1, C2 and C3 complexes with cisplatin were introduced into nanotubes, either physically or chemically. The complexes were reacted with anti-CD133 antibody to form the labeled product of A0-o-CX-chem-CD133. Cytotoxicity screening of all the complexes was performed on CHO cells. Data showed that both C2 and C3 Pt-complexes are more cytotoxic than C1. Flow-cytometry analysis showed that nanotubes conjugated to CD133 antibody have the ability to target cells expressing the CD133 antigen which is responsible for the emergence of resistance to chemotherapy and disease recurrence. The shortest survival rate was observed in the control mice group (K3) where no hyperthermic intraperitoneal chemotherapy procedures were used. On the other hand, the longest median survival rate was observed in the group treated with A0-o-C1-chem-CD133. In summary, we designed a novel drug delivery system based on carbon nanotubes loaded with Pt-prodrugs and functionalized with anti-CD133 antibodies. Our data demonstrates the effectiveness of the new drug delivery system and provides a novel therapeutic modality in the treatment of melanoma.

show abstract

“…Tumor-infiltrating T lymphocytes such as CD8 + and CD4 + T cells were observed both right and left tumors and tumorspecific cytotoxic T-lymphocyte (CTL) activity was augmented in the rats treated with MNHT. Jimbow et al also reported the anti-tumor immune responses induced by MNHT in mouse B16 melanoma models [22,23]. Thus, MNHT can kill not only heated tumors, but also non-heated tumors, including metastatic cancer cells.…”

Section: Induction Of Antitumor Immunity By Mnhtmentioning

confidence: 97%

“…For example, melanoma possesses tyrosinase as a melanin-forming enzyme which plays a role in the biosynthesis of melanin pigments. A melanoma-targeted MNP was developed by directly conjugating a tyrosine homolog, N-propionyl-cysteaminylphenol (NPrCAP) that is a tyrosinase substrate, or indirectly doing NPrCAP with an end of the polyethylene glycol Antibody-conjugated magnetite 10 nm Targets to human breast cancer, conjugated with radioactive indium [25] Antibody-conjugated magnetoliposome 10 nm Targets to tumor cells, stabilizes the colloidal solution [26][27][28][29] Magnetoliposomes with encapsulated antitumor drug 20-30 nm Controlled drug release [31,32] MNPs in needle shape 10 nm Organs with high blood flow [33,34] chain on the surface of dextran-coated MNPs [22,23]. When the NPrCAPconjugated MNPs (NPrCAP/M) were added to cultures of various cell lines in vitro, no substantial uptake by non-melanoma cells was observed, whereas the MNPs uptake by melanoma cell lines was observed in higher percentage [23].…”

Section: Magnetic Nanoparticles For Mnhtmentioning

confidence: 99%

Magnetic Nanoparticle-Mediated Hyperthermia and Induction of Anti-Tumor Immune Responses

Kobayashi

Ito

Honda

2016

Hyperthermic Oncology From Bench to Bedside

View full text Add to dashboard Cite

Magnetic nanoparticle-mediated hyperthermia (MNHT) can heat tumor tissue to the desired temperature without damaging surrounding normal tissue. The MNHT system consists of targeting tumor with functional magnetic nanoparticles (MNPs) and then applying an external alternating magnetic field (AMF) to generate heat in the MNPs. Temperature in the tumor tissue is increased to above 43 C, which causes necrosis of cancer cells but does not damage surrounding normal tissue. Among available MNPs, magnetite has been extensively studied. Recent years have seen remarkable advances in MNHT; both functional MNPs and AMF generators have been developed. By applying MNHT, heat shock proteins (HSPs) are highly expressed within and around tumor tissue, which causes intriguing biological responses such as tumor-specific immune response. These results suggest that MNHT is able to kill not only tumors exposed to heat treatment, but also unheated metastatic tumors at distant sites. Currently, some researchers have started clinical trials, suggesting that the time has come for clinical applications.

show abstract

Conjugation of Magnetite Nanoparticles with Melanogenesis Substrate, NPrCAP Provides Melanoma Targeted, <i>in Situ</i> Peptide Vaccine Immunotherapy through HSP Production by Chemo-Thermotherapy

Cited by 13 publications

References 56 publications

Hyperthermia mediated by dextran-coated La0.7Sr0.3MnO3 nanoparticles: in vivo studies

Hyperthermia mediated by dextran-coated La0.7Sr0.3MnO3 nanoparticles: in vivo studies

Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: a multidisciplinary study of peritoneal carcinomatosis

Magnetic Nanoparticle-Mediated Hyperthermia and Induction of Anti-Tumor Immune Responses

Contact Info

Product

Resources

About